Dara monotherapy
WebAs monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy C90 00604a ODMS 01/07/2024 TREATMENT: ... WebDaratumumab was previously granted accelerated approval in November 2015 as monotherapy for patients with multiple myeloma who have received at least three prior lines of therapy, including a...
Dara monotherapy
Did you know?
WebNov 16, 2015 · The FDA has granted an accelerated approval to the CD38-targeted monoclonal antibody daratumumab as a monotherapy for patients with multiple … WebDec 7, 2024 · Introduction: Daratumumab (DARA) is a CD38-targeting IgGκ monoclonal antibody with antimyeloma activity mediated by both on-tumor and immunomodulatory mechanisms of action.
WebNov 13, 2024 · Daratumumab (DARA) is a human IgGk monoclonal antibody targeting CD38 with a direct on-tumor and immunomodulatory mechanism of action that is approved for newly diagnosed and relapsed/refractory multiple myeloma (MM). ... DARA monotherapy demonstrated an encouraging response rate (ORR: 25%) in pts with R/R … WebNov 13, 2024 · Background: DARA, a human IgGκ monoclonal antibody targeting CD38, is approved in combination with bortezomib, melphalan, and prednisone (VMP) and bortezomib and dexamethasone (Vd) for newly diagnosed MM (NDMM) and relapsed MM (RMM), respectively. CyBorD is a commonly used immunomodulatory drug-sparing …
WebApr 8, 2024 · The other first option as upfront therapy recommended for TE patients is Dara-VTD (daratumumab, bortezomib, thalidomide, dexamethasone) regimen, approved after results from the phase III CASSIOPEIA trial [ 2] comparing VTD vs. Dara-VTD as induction (4 cycles) and consolidation (2 cycles) after ASCT. WebJul 29, 2024 · Daratumumab monotherapy in RRMM yielded an ORR of 29.2% and PFS of 3.7 months. 39 Concerning combination regimens, according to the result of the open …
WebFeb 2, 2024 · Daratumumab (DARA) is a human IgG-K monoclonal antibody (MoAb) targeting CD38 that is approved alone or in combination with bortezomib and …
WebNov 13, 2024 · Daratumumab (DARA) is a CD38-targeted antibody FDA-approved for the treatment of multiple myeloma (MM) and its efficacy has recently been demonstrated in the treatment of AL amyloidosis. DARA is conventionally given indefinitely until evidence of disease progression or intolerance for the treatment of MM. marche simili a pandoraWebMay 20, 2014 · Conclusions: DARA monotherapy in RR MM pts resulted in high single agent activity when administered at 16 mg/kg (46% ORR). The safety profile was … marchesi monferratoWebDec 3, 2015 · DARA acts through multiple immune effector-mediated mechanisms, including complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and antibody-dependent cellular phagocytosis. marchesi mexicoWebDec 4, 2024 · Dara, a human IgGκ monoclonal antibody that targets CD38, is approved as monotherapy and in combination with Vd, Rd, and pomalidomide-d for the treatment of … marchesi monzaWebNov 29, 2024 · DARA is a CD38-targeting IgG1κ monoclonal antibody with on-tumor and immunomodulatory mechanisms of action. Based on the demonstrated efficacy and favorable safety profile of DARA monotherapy in pts with relapsed/refractory MM (RRMM; Usmani SZ, et al. Blood 2016. 128 [1]:37-44), we hypothesized that DARA could delay … marchesi monza via manzoniWebNov 5, 2024 · Moreover, dara inhibits in vitro osteoclastogenesis and bone resorption. The present study investigated the impact of dara monotherapy on bone remodeling in pts with RRMM who have had ≥2 prior lines of therapy. Methods: REBUILD was a prospective, non-comparative, open-label, phase 2 study, conducted in six centers in Greece. marchesi mondo autoWebApr 9, 2016 · Interpretation: Daratumumab monotherapy showed encouraging efficacy in heavily pretreated and refractory patients with multiple myeloma, with a favourable … marchesi mortara